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Background: There are wide international differences in 1-year cancer survival. The UK and Denmark perform poorly compared
with other high-income countries with similar health care systems: Australia, Canada and Sweden have good cancer survival rates,
Norway intermediate survival rates. The objective of this study was to examine the pattern of differences in cancer awareness and
beliefs across these countries to identify where these might contribute to the pattern of survival.
Methods: We carried out a population-based telephone interview survey of 19 079 men and women agedX50 years in Australia,
Canada, Denmark, Norway, Sweden and the UK using the Awareness and Beliefs about Cancer measure.
Results: Awareness that the risk of cancer increased with age was lower in the UK (14%), Canada (13%) and Australia (16%) but was
higher in Denmark (25%), Norway (29%) and Sweden (38%). Symptom awareness was no lower in the UK and Denmark than other
countries. Perceived barriers to symptomatic presentation were highest in the UK, in particular being worried about wasting the
doctor’s time (UK 34%; Canada 21%; Australia 14%; Denmark 12%; Norway 11%; Sweden 9%).
Conclusion: The UK had low awareness of age-related risk and the highest perceived barriers to symptomatic presentation, but
symptom awareness in the UK did not differ from other countries. Denmark had higher awareness of age-related risk and few perceived
barriers to symptomatic presentation. This suggests that other factors must be involved in explaining Denmark’s poor survival rates. In
the UK, interventions that address barriers to prompt presentation in primary care should be developed and evaluated.
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International comparisons show wide differences in cancer
survival between high-income countries with good cancer
registration systems and good access to health care
(Berrino et al, 2007; Coleman et al, 2008). The International
Cancer Benchmarking Partnership (ICBP) was set up to examine
and explain survival differences between Australia, Canada,
Denmark, Norway, Sweden and the UK. For cancers of the lung,
breast, bowel and ovary diagnosed in 1995–2007, Australia,
Canada and Sweden had the highest survival and Denmark and
the UK the lowest; Norway had intermediate survival (Coleman
et al, 2011).
Survival differences between these countries were largely
explained by differences in 1-year survival (Coleman et al, 2011),
which may be a marker of late stage at diagnosis for some
cancers. High-resolution studies of survival suggest that interna-
tional differences are partly explained by differences in stage at
diagnosis for some cancers (Gatta et al, 2000; Sant et al, 2003, 2007;
Bouvier et al, 2010). Although there is emerging evidence
that differences in stage distribution do not explain all the
variation in short-term survival (Maringe et al, 2012 and
Michel Coleman, personal communication), patient delay in
presentation with symptoms and health care system delay in
referral or diagnosis are, nevertheless, considered likely to
contribute to later stage at diagnosis (Richards et al, 1999). There
is evidence for an important role for patient delay (Neal et al, 2008;
Neal, 2009).
Systematic reviews have found that low awareness of symptoms
is associated with patient delay for a range of common cancers
(Ramirez et al, 1999; Macleod et al, 2009). Other potential
influences on time to presentation include negative beliefs about
cancer outcomes (von Wagner et al, 2011) or barriers to
symptomatic presentation (Robb et al, 2009; Forbes et al, 2011)
and poor awareness of the risk of cancer. In particular, there is
evidence that older people are not aware that the risk of cancer
increases with age (Grunfeld et al, 2002) and are more likely to
delay presentation (Ramirez et al, 1999). In the UK, lower
awareness of cancer symptoms and more barriers to help-seeking
have been associated with longer anticipated delay in help-seeking
(Robb et al, 2009; Simon et al, 2010).
An individual’s cancer awareness and beliefs may also influence
whether they are referred promptly for investigation by their GP or
whether they receive effective treatments promptly. People with
high levels of awareness and positive beliefs about cancer outcomes
may be more likely to demand referral or may be more likely to
take up the offer of more aggressive treatment (Mitchell et al,
2007).
We aimed to examine whether people living in countries with
lower cancer survival (UK, Denmark) had lower cancer awareness,
more negative beliefs about cancer or more barriers to sympto-
matic presentation than people in countries with higher cancer
survival (Australia, Canada, Sweden).
MATERIALS AND METHODS
Overview. We carried out telephone surveys of people aged
X50 years in Australia (two states: New South Wales and
Victoria), Canada (four provinces: Alberta, British Columbia,
Manitoba, Ontario), Denmark, Sweden (two areas in central
Sweden: Uppsala-O¨rebro, Stockholm-Gotland), Norway and the
UK (three countries: England, Northern Ireland and Wales) to
match the areas included in the ICBP analyses of cancer survival
(Coleman et al, 2011). We aimed to achieve samples representative
of the populations of people agedX50. We selected this age group
because population-level cancer survival largely reflects survival in
the over-50s, in whom cancer is the commonest. We measured
cancer awareness and beliefs using the newly developed Awareness
and Beliefs about Cancer (ABC) measure (Simon et al, 2012). We
examined whether the pattern of cancer awareness and beliefs
followed the pattern expected from differences in cancer survival
and carried out statistical tests of differences between each country
and the UK.
Measures. The development, validation and structure of the ABC
are described in our accompanying paper (Simon et al, 2012). The
items in the ABC were informed by theoretical frameworks, such
as the Health Belief Model, and drew from other measures
previously used in population surveys (Paul et al, 2006; Stubbings
et al, 2009; Park and Clery, 2010) but were designed to identify key
items that could differ between countries rather than test any one
theoretical model. We aimed to harmonise the measures across all
six countries focusing on conceptual and cultural equivalence
rather than relying simply on verbatim translation. After cognitive
testing and assessment of test–retest reliability and content validity
in UK English, the ABC was translated and made culturally
appropriate for each country. A panel of experts adapted the
measure to make it locally appropriate in collaboration with
international colleagues so that equivalence of meaning was not
lost, then cognitive testing in each country was carried out. For the
French Canadian, Danish, Norwegian and Swedish versions, we
estimated equivalence of meaning with the English version
quantitatively, and then carried out several further cognitive
interviews among bilingual speakers of English and each of the
four languages.
In this paper, we provide results of international comparisons
for items related to recognition of cancer symptoms (from a list of
11 possible symptoms), awareness that cancer risk is higher in
people agedX70 years than at a younger age, beliefs about barriers
to symptomatic presentation (items asking whether embarrass-
ment, fear about what the doctor might find, worry about wasting
the doctor’s time and being too busy might put them off going to
the doctor) and negative beliefs about cancer outcomes (items
asking whether participants agreed that ‘many people with cancer can
expect to continue with normal activities and responsibilities’, ‘cancer
can often be cured’ and ‘a diagnosis of cancer is a death sentence’).
We also collected data on age, sex, language spoken at home,
relationship status, experience of cancer (self, family and friends),
self-rated health and level of education, mapping categories of
education in each country onto the International Standard
Classification of Education (UNESCO, 2006).
Data collection. Data collection were carried out by Ipsos MORI
using computer-assisted live telephone interviews. All men and
women aged X50 years living in private households and able to
understand an official language of the country were eligible.
In Australia, Canada and the UK, the sampling frames were
commercially available electronic landline telephone listings,
because sampling frames of all adults aged X50 years are not
freely available. Telephone numbers were randomly selected in a
number proportionate to population size of each region. The final
two digits of each selected number were replaced with two random
numbers, which brought unlisted numbers into the sampling
frame. If the person answering the telephone reported that one or
more people aged X50 years lived in the household, that
household was considered eligible. If more than one person aged
X50 years lived in the household, the Rizzo method was used to
select one person to be interviewed; this gives an equal chance of
selection to all eligible people living in the household (Rizzo et al,
2004). In Denmark, Norway and Sweden, the sampling frames
were national population registers, which include name, address
and date of birth. We randomly selected people aged X50 years
(without stratifying by geography) and identified their telephone
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numbers (mobile or landline) from electronic telephone listings
using their names and addresses.
Interviewers were randomly allocated telephone numbers. Each
telephone number was called up to seven times at different times of
day. Experienced interviewers listened to a random 10% of calls to
assess quality and provide performance feedback. The order of the
items in ‘lists’ were rotated randomly to avoid bias introduced by
ordering.
Interviewers were trained to undertake the survey accurately,
sensitively and consistently. Interviews in Denmark, Norway,
Sweden and among French-speaking Canadians were carried out
by native language speakers. Interviewers offered participants
contact details of a local cancer support charity or other agency if
they showed any sign of distress.
Interviews were carried out in Australia, Denmark and the UK
from May to July 2011, in Canada in June and July 2011 and in
Norway and Sweden in August and September 2011, to avoid
summer holiday periods, which were different in each country.
Sample size. We aimed to achieve a sample size of 2000
participants in each country. We based sample size calculations
on the results of a UK survey of cancer awareness (Robb et al,
2009), in which 45% recognised a persistent cough as a warning
sign for cancer. A sample size of 2000 in each country was found to
be sufficient to show a 6% difference in recognition of persistent
cough as a symptom of cancer between the UK and another
country, with 90% power at the 5% level of significance.
Analysis. We calculated response rates using the American
Association for Public Opinion Research (AAPOR) conventions,
to provide comparable response rates after allowing for variations
in survey methods (The American Association of Public Opinion
Research, 2011). This is important because in three of the countries
(Australia, Canada and the UK) we did not know the denominator
of eligible people and therefore could not calculate the response
rate in the usual way. We calculated the ‘minimum response rate’
as the number of complete interviews divided by the number of all
possible interviews (the number of interviews among eligible
people plus the number of households where eligible people were
known to live, but where the interview could not be completed
(e.g., refusal, interview broken off) plus the number of all
households of unknown eligibility). It represents the response rate
assuming that all households that we could not assess for eligibility
were eligible (equivalent to AAPOR response rate formula 1). It is
likely to underestimate response rates because it is likely that many
households were ineligible. We also calculated the ‘estimated
response rate’ as the number of completed interviews divided by
the estimated number of eligible individuals, based on the
proportion of households that were eligible out of those assessed
for eligibility (equivalent to AAPOR response rate formula 3).
Using responses to the 11 items on cancer symptom awareness
(unexplained lump or swelling, persistent unexplained pain,
unexplained bleeding, a persistent cough or hoarseness, a change
in bowel or bladder habits, a persistent difficulty in swallowing, a
change in the appearance of a mole, a sore that does not heal,
unexplained night sweats, unexplained weight loss, unexplained
tiredness; response categories: yes/no), we computed the total
number of symptoms recognised.
We calculated aggregate scores for beliefs about barriers to
symptomatic presentation and beliefs about cancer outcomes,
based on results of the factor analysis as described in our linked
paper (Simon et al, 2012). Briefly, we generated two new variables,
one based on four barrier items: too embarrassed, too busy,
worried about wasting the doctor’s time, worried about what the
doctor might find) and the other based on three belief items
(‘cancer can often be cured’, ‘a diagnosis of cancer is a death
sentence’, ‘people with cancer can expect to continue with normal
activities and responsibilities’). We carried out factor analysis of the
inter-correlations of the items that identified the underlying
theoretical factors that accounted for most of the common
variation; these were used to weight the items before summing
into aggregate scores. For both the aggregate scores, we
standardised the results so that the minimum score was 0 and
the maximum 50, a higher score reflecting more negative beliefs or
more barriers, and calculated means and 95% confidence intervals.
We also calculated the proportion of participants who agreed or
disagreed with each individual barrier item (combining response
categories ‘yes often’ and ‘yes sometimes’) and each individual
belief about cancer outcomes (combining the response categories
‘strongly agree’ with ‘tend to agree’ and ‘tend to disagree’ with
‘strongly disagree’).
We weighted percentages and means to allow for design effects
introduced by variations between countries in sampling methods
and household size (further details provided in online supplement;
Supplementary Table S2 shows the sources used to apply non-
representativeness weights and variables used in weighting). We
age–sex-standardised weighted percentages and adjusted means for
age and sex to allow for differences in age–sex distribution between
the countries’ samples, using the European Standard Population.
We fitted multivariable models (logistic or linear regressions as
appropriate) to examine the associations between the cancer
awareness and belief variables (mean number of cancer symptoms
recognised, awareness of age-related risk of cancer, beliefs about
cancer outcomes and barriers to symptomatic presentation) and
country, with UK as reference category.
Bootstrapping was conducted for the linear regression analyses,
because the assumption that the residuals were normally
distributed did not hold. This involved taking multiple samples
with replacement and using these multiple samples to generate the
regression coefficients and standard errors (Carpenter and Bithell,
2000).
We weighted the odds ratios and means to allow for design
effects (further details in the online supplement). Our first model
included age (50 59, 60 69,X70 years) and sex, and the second
included educational level, experience of cancer (self or among
family and friends, none), living alone (yes, no) and self-reported
health (good, fair, poor), to examine the extent to which differences
in these might explain the differences between the countries in
levels of cancer awareness or beliefs. Data were analysed using
SPSS for Windows, Release 15.0.0, 2006 (Chicago, IL, USA).
Where particular demographic groups were over- or under-
represented (based on the demographic profile of the population
aged X50 years in each country obtained from routine
data sources), we then weighted the percentages, means and odds
ratios for these. In practice, this meant that we weighted
for age, sex and education in every country (except for education
in Denmark); we also weighted for marital status in Northern
Ireland and Wales, ancestry (Canada), country of birth
and metropolitan/rural residence (Australia), country of origin
(Norway and Sweden) and region (Northern Ireland and Wales;
further details provided in the online supplement; see
Supplementary Table S2).
RESULTS
Response. Nineteen thousand and seventy nine people completed
the ABC measure. Response rates are shown in Table 1. The
minimum response rate was lowest in the countries where random
digit dialling was used, because the number of households for
which we did not know eligibility was high. In the Scandinavian
countries, nearly all households telephoned were eligible, because
we used population registers to select households where someone
aged X50 years lived. The estimated response rates were very
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Table 1. Response rates
Australia Canada Denmark Norway Sweden UK
Total number of households with connected telephone
numbers approached
35 730 46672 5369 8921 7411 80 210
Number of households of unknown eligibilitya 20 719 34828 899 1922 1901 55 979
Number of households of known eligibility 15 011 11844 4470 6999 5510 24 231
Number of households in which the individual declined
to take part either during or after assessment of eligibility
433 1195 2337 4726 3345 3468
Number of ineligible householdsa 10 119 8571 12 24 19 13 234
Number of eligible householdsa 4892 3273 4458 6975 5491 10 997
Proportion of households eligible among those
assessed for eligibility (%)
32.6 27.6 99.7 99.7 99.7 45.4
Completed interviews 4002 2064 2000 2009 2039 6965
Minimum response rate (%)b 15.9 5.4 31.5 23.2 28.0 10.5
Estimated response rate (%)c 47.4 38.8 31.6 23.0 27.5 40.0
aA household was eligible if one or more people aged X50 years lived in the household.
bThe minimum response rate represents the response rate assuming all households that we could not assess for eligibility were eligible, in other words the lowest possible response rate. It is
calculated as the number of complete interviews divided by the number of interviews plus the number of incomplete interviews among eligible people (refusals and break-offs plus
non-contacts) plus the number of all households of unknown eligibility (equivalent to the American Association for Public Opinion Research response rate formula 1).
cThe estimated response rate respresents the response rate after adjusting the size of the denominator for the likely proportion of housholds that were eligible. It is calculated by assuming that
the proportion eligible among households of unknown eligibility is the same as the proportion of those tested for eligibility who were eligible (equivalent to American Association for Public
Opinion Research response rate formula 3).
Table 2. Description of sample populations
Australia UK
Age group (years)
New South
Wales
Victoria Canadaa Denmark Norway Swedenb England
Northern
Ireland
Wales
Women
50–69 795 (39.7) 796 (39.8) 988 (47.9) 804 (40.2) 716 (35.6) 801 (39.3) 949 (40.2) 1092 (47.3) 952 (41.4)
X70 457 (22.8) 472 (23.6) 342 (16.6) 261 (13.1) 216 (10.8) 310 (15.2) 517 (21.9) 378 (16.4) 431 (18.8)
Total 1252 (62.6) 1268 (63.4) 1330 (64.5) 1065 (53.3) 932 (46.4) 1111 (54.5) 1466 (62.1) 1470 (63.7) 1383 (60.2)
Men
50–69 497 (24.8) 473 (23.6) 563 (27.3) 706 (35.3) 775 (38.6) 668 (32.8) 618 (26.2) 613 (26.6) 658 (28.6)
X70 247 (12.3) 254 (12.7) 171 (8.3) 229 (11.5) 302 (15.0) 260 (12.8) 267 (11.3) 219 (9.5) 255 (11.1)
Total 744 (37.2) 727 (36.3) 734 (35.6) 935 (46.8) 1077 (53.6) 928 (45.6) 885 (37.5) 832 (36.1) 913 (39.7)
All
50–69 1292 (64.6) 1269 (63.4) 1551 (75.2) 1510 (75.5) 1491 (74.2) 1469 (72.1) 1567 (66.4) 1705 (73.9) 1610 (70.0)
X70 704 (35.2) 726 (36.3) 513 (24.9) 490 (24.6) 518 (25.8) 570 (28.0) 784 (33.2) 597 (25.9) 686 (29.9)
Missing age 5 (0.2) 6 (0.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 9 (0.4) 5 (0.2) 2 (0.1)
Total 2001 (100) 2001 (100) 2064 (100) 2000 (100) 2009 (100) 2039 (100) 2360 (100) 2307 (100) 2298 (100)
Speaks official language at
homec
1780/1996
(89.2)
1711/1995
(85.8)
1990/2058
(96.7)
1985/2000
(99.3)
1970/2009
(98.1)
1969/2038
(96.6)
2315/2350
(98.5)
2287/2300
(99.4)
2288/ 2293
(99.8)
Educated to university
degree level
623/1980
(31.5)
678/1980
(34.2)
706/2051
(34.4)
582/1994
(29.2)
927/1999
(46.4)
729/2037
(35.8)
556/2317
(24.0)
505/2267
(22.3)
506/2278
(22.2)
Married or living with partner 1096/1984
(55.2)
1102/1988
(55.4)
1201/2054
(58.5)
1514/1998
(75.8)
1453/2006
(72.4)
1432/2037
(70.3)
1215/2339
(51.9)
1286/2291
(56.1)
1281/2287
(56.0)
Experience of cancer (self,
family or friend)
1655/1992
(83.1)
1644/1994
(82.4)
1758/2061
(85.3)
1705/2000
(85.3)
1696/2008
(84.5)
1664/2037
(81.7)
1876/2347
(79.9)
1801/2296
(78.4)
1890/2291
(82.5)
Self-rated health status
(good/very good)
1496/1994
(75.0)
1553/1989
(78.1)
1624/2063
(78.7)
1499/1993
(75.2)
1568/2001
(78.4)
1442/2034
(70.9)
1695/2345
(72.3)
1624/2296
(70.7)
1541/2288
(67.4)
Values are n (%).
aAlberta, British Columbia, Manitoba, Ontario.
bUppsala-O¨rebro, Stockholm-Gotland.
cOfficial languages: Australia: English (de facto official language); Canada: English, French; Denmark: Danish; Norway: Norwegian; Sweden: Swedish; UK: English, Welsh, Ulster Scots, Irish.
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similar to the minimum response rates in the Scandinavian
countries, because the proportion of ineligible households was low.
The estimated response rate ranged from 23% in Norway to 47% in
Australia.
Characteristics and representativeness of sample populations.
On average, 29% of the participants were aged X70 years (25% in
Denmark to 36% in Australia) (Table 2); this proportion was
roughly representative of the age distribution of the population (see
Supplementary Table S1 online). Women were slightly over-
represented (59%, vs 53% in the population agedX50 years), with
the Canadian sample having the highest proportion of women
(65%) and Norway the lowest (46%; Table 2). The proportion of
participants with a university degree was the lowest in the UK
(23%) and the highest in Norway (46%; Table 2). The proportion
of the countries’ populations agedX50 years with a degree ranges
from 10% to 30%.
More than 96% of participants spoke an official language in all
countries’ samples except in Australia, where 88% spoke English,
the de facto official language, at home. Between 52% and 76% were
married or living with a partner. Across the countries, between
79% and 86% of participants reported that they had experience of
cancer, either themselves or in a close friend or family member,
and 67–79% rated their health status as ‘good’ or ‘very good’.
Cancer awareness. The mean number of symptoms recognised
out of 11 was relatively high and varied little between Wales (8.21)
and Canada (8.70), with the mean in Sweden somewhat lower
(7.71) (Table 3). Controlling for education slightly attenuated the
differences, but the pattern remained the same. Controlling for
Table 3. Awareness of cancer symptoms and age-related risk of cancer
Number of
symptoms
recognised out of
11 (95% CI) (mean
adjusted for age
and sex)
Knew that 70-year olds most
likely to be diagnosed with
cancer (rather than
30-year olds, 50-year olds or
people of any age)
n (%)a OR (95% CI)b
UK 8.22 (8.14–8.30) 747/6839
(13.6)
1.00 (Reference)
England 8.23 (8.13–8.33) 285/2384
(13.8)
Northern
Ireland
8.53 (8.43–8.62) 218/2267
(10.7)
Wales 8.21 (8.12–8.31) 244/2268
(11.3)
Denmark 8.35 (8.26–8.44) 481/1962
(24.8)
2.15
(1.83–2.53)
Norway 8.49 (8.40–8.58) 576/1981
(28.7)
2.63
(2.25–3.08)
Sweden 7.71 (7.62–7.81) 752/2015
(37.8)
4.05
(3.48–4.72)
Australia 8.34 (8.27–8.41) 563/3894
(15.5)
1.18
(1.01–1.37)
New South
Wales
8.37 (8.27–8.47) 254/1956
(13.8)
Victoria 8.29 (8.18–8.40) 309/1938
(17.9)
Canada 8.70 (8.60–8.81) 248/2045
(13.3)
1.02
(0.83–1.24)
Abbreviations: CI¼ confidence interval; OR¼odds ratio. Means, percentages and odds
ratios for all UK countries combined, both Australian states combined and all Canadian
provinces combined are weighted for unequal sampling fraction by country (UK), state
(Australia) or province (Canada). All means, percentages and odds ratios are weighted for
different probabilities of selection by household size.
aDirectly age–sex standardised using European Standard Population.
bAdjusted for age and sex.
Table 4. Barriers to symptomatic presentation: would any of these put
you off going to the doctor with a symptom that might be serious?
Individual items
n (%)a OR (95% CI)b
I would be too embarrassed
UK 1127/6937 (14.5) 1.00 (Reference)
England 332/2345 (14.3)
Northern Ireland 431/2300 (18.1)
Wales 364/2292 (15.4)
Denmark 117/1998 (5.8) 0.36 (0.29–0.45)
Norway 189/2007 (9.4) 0.62 (0.51–0.75)
Sweden 184/2027 (9.2) 0.60 (0.50–0.72)
Australia 450/3980 (11.6) 0.77 (0.66–0.90)
New South Wales 231/1991 (12.1)
Victoria 219/1989 (11.0)
Canada 203/2063 (9.6) 0.62 (0.51–0.76)
I would be worried about wasting the doctor’s time
UK 2330/6935 (34.3) 1.00 (Reference)
England 788/2348 (34.3)
Northern Ireland 775/2300 (33.6)
Wales 767/2287 (33.5)
Denmark 235/1995 (11.7) 0.25 (0.22–0.30)
Norway 216/2005 (10.9) 0.23 (0.20–0.27)
Sweden 189/2036 (9.3) 0.20 (0.17–0.23)
Australia 575/3983 (14.2) 0.32 (0.28–0.36)
New South Wales 283/1996 (13.8)
Victoria 292/1987 (14.5)
Canada 428/2062 (21.1) 0.50 (0.43–0.58)
I would be worried about what the doctor might find
UK 2023/6925 (27.5) 1.00 (Reference)
England 645/2345 (27.4)
Northern Ireland 689/2291 (29.5)
Wales 689/2289 (29.2)
Denmark 478/1986 (23.9) 0.83 (0.72–0.95)
Norway 390/1997 (19.8) 0.65 (0.56–0.75)
Sweden 469/2033 (23.1) 0.79 (0.69–0.90)
Australia 885/3974 (22.0) 0.73 (0.65–0.82)
New South Wales 429/1992 (21.5)
Victoria 456/1982 (22.7)
Canada 538/2061 (25.4) 0.90 (0.78–1.04)
I am too busy to make time to go to the doctor
UK 1522/6942 (22.8) 1.00 (Reference)
England 497/2350 (22.8)
Northern Ireland 519/2300 (23.5)
Wales 506/2292 (23.1)
Denmark 345/1997 (17.4) 0.68 (0.58–0.79)
Norway 414/2001 (20.8) 0.87 (0.75–1.01)
Sweden 380/2034 (19.2) 0.81 (0.70–0.94)
Australia 860/3981 (23.7) 1.04 (0.91–1.18)
New South Wales 429/1994 (23.6)
Victoria 431/1987 (23.7)
Canada 586/2062 (29.4) 1.35 (1.15–1.58)
Percentages and odds ratios for all UK countries combined, Denmark, Norway, Sweden, both
Australian states combined and all Canadian provinces combined are weighted for unequal
sampling fraction by country (UK), state (Australia) or province (Canada). All percentages and
odds ratios are weighted for different probabilities of selection by household size.
aDirectly age–sex standardised using European Standard Population.
bAdjusted for age and sex.
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living alone, self-rated health and experience of cancer, and
weighting for non-representativeness, made little difference to the
pattern of results.
There were large international differences in the proportions
knowing that 70-year olds were at greater risk of cancer than younger
people (Table 3). Awareness of age-related risk was the lowest in the
UK (14%; and especially low in Northern Ireland and Wales) and the
highest in Sweden (38%). Canada and Australia had similar levels of
awareness of age-related risk compared with the UK. Controlling for
education attenuated the size of the differences slightly, but the pattern
remained the same. Controlling for living alone, self-rated health and
experience of cancer, and weighting for non-representativeness, made
little difference to the results.
Beliefs about barriers to symptomatic presentation and about
cancer outcomes. People in the UK were most likely to report that
embarrassment would put them off going to the doctor with a
symptom that might be serious (15%) and those in Denmark the
least likely (6%) (Table 4). People in the UK were also most likely
to report that worry about wasting the doctor’s time would put
them off going to the doctor (34%) and those in Sweden the least
likely (9%). People in the UK were also most likely to report that
worry about what the doctor would find might put them off going
to the doctor (28%), although the international differences were
less marked: people in Norway were least likely to report this
(20%). People in Canada were most likely to report that being too
busy would put them off going to the doctor (29%) and those in
Denmark the least likely (17%). Using the aggregate score,
Denmark had the lowest mean barriers to symptomatic presenta-
tion (4.95/50), followed by Sweden, Norway, Australia and Canada
(Table 5). The UK had the highest mean barriers to symptomatic
presentation (8.29/50).
Very high proportions of people agreed that cancer could often
be cured, with those in Sweden and Norway most likely to agree,
and those in Australia and Canada least likely to agree (Table 6).
Similarly, a high proportion of people disagreed that a diagnosis of
cancer was a death sentence and agreed that people with cancer
could expect to continue with normal activities and responsibilities,
with small differences between countries. There were also small
differences between the countries in beliefs about cancer outcomes
score: Norway had the lowest mean score (9.72/50; fewer negative
beliefs) and Australia the highest (12.82/50; more negative beliefs)
(Table 5).
For both sets of analyses, controlling for age, sex, education,
living alone, self-rated health and experience of cancer, and
weighting for non-representativeness, made little difference to the
pattern of results.
DISCUSSION
People in the UK, which has relatively poor cancer survival, had
lower awareness that the risk of cancer increases with age and
reported more barriers to symptomatic presentation (especially
worry about wasting the doctor’s time) than other countries.
However, people in Denmark, who also have relatively poor cancer
survival, had high awareness of age-related risk of cancer and few
barriers to symptomatic presentation. Awareness of cancer
symptoms was high and beliefs about cancer outcomes were
positive for all participating countries and differences between the
countries were small. We found no evidence that the overall
pattern of cancer awareness and beliefs followed the overall pattern
of 1-year cancer survival across the countries.
To our knowledge, this is the first study examining differences
in cancer awareness and beliefs between high-income countries. It
is unlikely that methodological limitations explain the results. We
developed harmonised versions of the ABC to measure the
constructs in each country and harmonised the survey methods,
using a single provider to carry out the sampling and interviews.
We achieved samples that were representative, in terms of age, sex
and education, of the underlying populations. Controlling for any
differences in age, sex and education distribution between
populations and doing sensitivity analyses to allow for under-
representativeness of certain demographic groups made very little
difference to the results. The large sample sizes meant that we were
confident about the precision of our estimates, although it also
meant that small differences were statistically significant even
where actual differences were not likely to be of great public health
significance. Moreover, where proportions reporting an outcome
are high (e.g., in beliefs about cancer outcomes), odds ratios
become unreliable as measures of relative risk (Davies et al, 1998).
In view of this, our approach to interpreting the results was to
focus on absolute differences between the countries that were likely
to be of public health significance.
There was some variation in estimated response rates between
countries, with lower rates in the Scandinavian countries and the
highest rate in Australia. It is difficult to know whether the
response rates achieved in Australia, Canada and the UK are
comparable to other surveys, because few reports of random digit
dialling surveys in these countries have reported response rates
according to AAPOR conventions. In Scandinavian countries, where
there are population registers, telephone surveys often achieve higher
response rates than this, but it is more usual for the researchers to
write to people before telephoning them (e.g., Feveile et al, 2007). We
chose not to write to potential participants in advance in the
Scandinavian countries, because it would have increased the variation
in survey methods. Despite the variation in response rates, the age
distribution of the samples were broadly similar to the national
populations except for some differences in gender balance (more
women) and higher levels of education (which often happens in health
surveys). However, weighting made little difference to the estimates of
cancer awareness or beliefs that suggests that under- or over-
representation of particular groups did not significantly influence the
pattern of cancer awareness and beliefs.
Table 5. Beliefs about barriers to symptomatic presentation and cancer
outcomes – aggregate scores
Mean score out of 50 (95% CI)
Barriers to
symptomatic
presentation
Negative beliefs
about cancer
outcomes
UK 8.29 (7.87–8.72) 11.14 (10.71–11.58)
England 8.85 (8.33–9.38) 10.75 (10.21–11.29)
Northern Ireland 9.30 (8.75–9.86) 11.93 (11.37–12.48)
Wales 9.21 (8.59–9.83) 11.11 (10.55–11.68
Denmark 4.95 (4.59–5.31) 12.66 (12.19–13.13)
Norway 5.28 (4.90–5.66) 9.72 (9.25–10.19)
Sweden 5.29 (4.95–5.64) 12.06 (11.63–12.52)
Australia 5.92 (5.58–6.26) 12.82 (12.38–13.25)
New South Wales 6.65 (6.06–7.25) 12.48 (11.72–13.23)
Victoria 6.52 (5.97–7.08) 12.18 (11.49–12.87)
Canada 6.52 (6.06–6.98) 12.39 (11.84–12.93)
Abbreviation: CI¼ confidence interval. Note: a higher score on barriers to symptomatic
presentation indicates more barriers; a higher score on negative beliefs about cancer
outcomes indicates more negative beliefs about cancer outcomes. All means adjusted for
age and sex. Means for all UK countries combined, both Australian states combined and all
Canadian provinces combined are weighted for unequal sampling fraction by country (UK),
state (Australia) and province (Canada). All means are weighted for different probabilities of
selection by household size.
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We calculated aggregate scores for two sets of items (beliefs about
cancer outcomes and about barriers to symptomatic presentation),
because factor analysis provided strong evidence that responses to
each set of items were driven by common underlying factors: broad
perceptions about either beliefs about cancer outcomes or barriers to
symptomatic presentation (Simon et al, 2012). The mean differences
between countries in the aggregate scores are more likely to represent
real differences and are more precise (with narrower confidence
intervals) than the responses to the individual items.
We monitored the three most widely distributed national
newspapers in each of the participating countries for 2 weeks
before and during fieldwork, focusing on stories or campaigns that
would have affected all or most of the geographical area covered
reported in the first three pages. In Denmark and Norway, there
were no relevant news stories. In Sweden, there were stories about
breast screening, HPV vaccination and the quality of cancer care.
In the UK, there was a story about a blood test to identify ovarian
cancer early, and a negative story about the quality of cancer care
in the NHS. In Canada, there was a story about a celebrity with oral
cancer but no details about symptoms, and a story about the
quality of care in cervical screening. In Australia, there were stories
about men’s health checks for a range of health issues (not just
cancer), dietary risk factors for cancer and mammography.
Although we cannot rule out an effect of these stories on our
results, none appeared sufficiently specific to have influenced
population levels of cancer awareness or beliefs to the extent that
they would explain any observed international differences.
The biggest differences in cancer awareness and beliefs between
the participating countries were in beliefs about barriers to
symptomatic presentation and awareness of age-related risk, with
the UK having the highest level of barriers and the lowest
awareness of age-related risk; this is consistent with previous UK
surveys (Robb et al, 2009; Forbes et al, 2011). Our study was not
designed to address the underlying reasons for international
differences; that would be for future studies. We speculate that
people’s worry about wasting the doctor’s time in the UK could be
shaped by a belief that they might be told they were wasting the
doctor’s time if they presented, that others might judge that they
Table 6. Beliefs about cancer outcomes – individual items
n (%)a OR (95% CI)b
Agree with ’Cancer can often be cured’
UK 6228/6796 (92.8) 1.00 (Reference)
England 2108/2290 (92.8)
Northern Ireland 2086/2251 (92.8)
Wales 2034/2255 (90.4)
Denmark 1786/1960 (91.0) 0.81 (0.65–1.00)
Norway 1872/1979 (94.6) 1.38 (1.08–1.77)
Sweden 1887/2006 (94.0) 1.25 (0.98–1.58)
Australia 3422/3844 (88.9) 0.65 (0.54–0.78)
New South Wales 1703/1926 (88.7)
Victoria 1719/1918 (89.3)
Canada 1768/2028 (88.3) 0.59 (0.47–0.72)
Disagree with ’A diagnosis of cancer is a death sentence’
UK 4885/6629 (77.4) 1.00 (Reference)
England 1706/2231 (77.8)
Northern Ireland 1531/2200 (69.5)
Wales 1648/2198 (75.8)
Denmark 1435/1954 (73.6) 0.82 (0.71–0.94)
Norway 1500/1959 (76.5) 0.95 (0.82–1.09)
Sweden 1559/2020 (77.2) 0.99 (0.86–1.14)
Australia 2785/3787 (73.7) 0.83 (0.74–0.94)
New South Wales 1406/1906 (73.9)
Victoria 1379/1881 (73.4)
Canada 1519/2018 (75.4) 0.92 (0.79–1.08)
Agree with ’People with cancer can expect to continue with normal activities and responsibilities’
UK 6115/6680 (92.6) 1.00 (Reference)
England 2074/2256 (92.7)
Northern Ireland 2023/2218 (91.8)
Wales 2018/2206 (91.8)
Denmark 1687/1929 (87.6) 0.55 (0.45–0.68)
Norway 1864/1972 (94.4) 1.36 (1.07–1.74)
Sweden 1816/1971 (92.2) 0.92 (0.74–1.15)
Australia 3421/3806 (90.0) 0.73 (0.61–0.88)
New South Wales 1689/1905 (89.0)
Victoria 1732/1901 (91.2)
Canada 1778/2023 (88.8) 0.92 (0.74–1.15)
Abbreviation: CI¼ confidence interval. Note: an odds ratio41 indicates less negative beliefs about cancer. Percentages and odds ratios for all UK countries combined, both Australian states
combined and all Canadian provinces combined are weighted for unequal sampling fraction by country (UK), state (Australia) or province (Canada). All percentages and odds ratios are
weighted for different probabilities of selection by household size.
aDirectly age–sex standardised using European Standard Population.
bAdjusted for age and sex.
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should not waste the doctor’s time or that they should not waste
public resources. British people could be more concerned about
embarrassment because of the traditional ‘stiff upper lip’. Barriers
to symptomatic presentation in Britain warrant further research to
inform interventions to promote early presentation.
The pattern of differences in cancer awareness and beliefs between
the participating countries did not follow the pattern of differences in
survival, but there was some evidence that it followed cultural/
language demarcations: Scandinavian people had lower levels of
barriers to symptomatic presentation and better awareness of age-
related risk than people in the Commonwealth countries, but further
studies are needed to identify the origins of these differences.
Although we found no evidence that the international pattern of
cancer awareness and beliefs followed the 1-year survival pattern,
our results do not rule out an association between cancer
awareness and beliefs and cancer survival at an individual level,
because it was an ecological analysis looking at average levels of
cancer awareness and beliefs.
Other factors, for example, delay in primary care referral or
delay in diagnosis in secondary care, may contribute to delay in
diagnosis. It has been hypothesised that poor cancer survival in
Denmark is related to gate-keeping by primary care doctors
(Vedsted and Olesen, 2011), although a Danish study found that a
large proportion of delay in diagnosis was attributable to delay
between the GP initiating investigations for cancer and the start of
treatment (Hansen et al, 2011). Furthermore, other analyses from
the ICBP exploring stage and survival data for ovarian (Maringe
et al, 2012) and breast cancer (Michel Coleman, personal
communication), suggest that differences in access to treatments
or tumour biology may also be having a role in differ-
ences in survival rates, although differences in staging procedures
make comparisons difficult. All these issues – beliefs and
behaviours in primary care, diagnostic pathways and availability
of treatments – are now being studied across the ICBP countries.
This will help to work out the relative importance of each factor in
determining the 1-year cancer survival rates in each country.
Our findings have some specific implications for individual
countries. In Denmark, poor 1-year cancer survival rates are not
likely to be due to poor cancer awareness and negative beliefs in the
population, and the causes must be sought elsewhere. In the UK,
interventions to promote early presentation might usefully focus
on addressing awareness of the age-related risk and increasing the
public’s confidence to approach the GP with possible cancer
symptoms.
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